IAS-USA update drug resistance mutations (2025)

Simon Collins, HIV i-Base

This 2025 edition of the International Antiviral Society–USA (IAS–USA) drug resistance mutations list updates the November 2022 recommendations.

A summary of new drug resistance includes several new mutations in integrase. See Table 1 below.

Other changes include the addition of figure bars and user notes for the entry inhibitors fostemsavir and ibalizumab.

Antiretroviral drugs that are no longer recommended or manufactured are now listed at the bottom of the drug class and are shaded in grey. Their user notes are retained for historical reference.

Table 1. Summary of mutation updates to the 2025 figure bars.

Drug Figure bar changes (mutation type)
Doravirine Added A98G (minor)
Dolutegravir Added S147G (minor)
Cabotegravir Added L74I (major), but relevant for subtype A6 only.
Lenacapavir Added K70H (major)
Updated K70N (major)
Updated L56I (major)
Updated N74D (major)
Raltegravir Added G118R (major)
Added G140C (minor)
Elvitegravir Added G118R (major)
Added E138A/K (minor)
Added G140A/C/S (minor)

References

  1. Wensing AM et al. 2025 Update of the Drug Resistance Mutations. Topics in HIV Medicine. Volume 33, Issue 2, (May 2025).
    https://www.iasusa.org/wp-content/uploads/2025/05/33-2-457.pdf (PDF)

Links to other websites are current at date of posting but not maintained.